CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week) Sep 22, 2021 8:00am EDT
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021 Sep 21, 2021 8:00am EDT
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group Sep 20, 2021 10:18am EDT
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A Sep 13, 2021 6:00am EDT
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms Sep 09, 2021 8:29pm EDT
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials Sep 02, 2021 6:40pm EDT
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws Sep 02, 2021 5:32pm EDT
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs Aug 26, 2021 5:02pm EDT
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group Aug 25, 2021 8:34am EDT
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival Aug 25, 2021 8:00am EDT
